These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 24641191)

  • 61. Generation of the induced pluripotent stem cell line (ZSPHARi001-A) from a patient with recessive dystrophic epidermolysis bullosa carrying compound heterozygous mutation in the COL7A1 gene.
    Zhang Y; Fan J; Lu G; Xu G; Lv Q
    Stem Cell Res; 2022 Apr; 60():102672. PubMed ID: 35121199
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Rat model for dominant dystrophic epidermolysis bullosa: glycine substitution reduces collagen VII stability and shows gene-dosage effect.
    Nyström A; Buttgereit J; Bader M; Shmidt T; Ozcelik C; Hausser I; Bruckner-Tuderman L; Kern JS
    PLoS One; 2013; 8(5):e64243. PubMed ID: 23717576
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Correction of Recessive Dystrophic Epidermolysis Bullosa by Transposon-Mediated Integration of COL7A1 in Transplantable Patient-Derived Primary Keratinocytes.
    Latella MC; Cocchiarella F; De Rosa L; Turchiano G; Gonçalves MAFV; Larcher F; De Luca M; Recchia A
    J Invest Dermatol; 2017 Apr; 137(4):836-844. PubMed ID: 28027893
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Deconstructing progressive inflammatory fibrosis in recessive dystrophic epidermolysis bullosa.
    Ebens CL
    EMBO Mol Med; 2021 Oct; 13(10):e14864. PubMed ID: 34515407
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Amelioration of epidermolysis bullosa by transfer of wild-type bone marrow cells.
    Tolar J; Ishida-Yamamoto A; Riddle M; McElmurry RT; Osborn M; Xia L; Lund T; Slattery C; Uitto J; Christiano AM; Wagner JE; Blazar BR
    Blood; 2009 Jan; 113(5):1167-74. PubMed ID: 18955559
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A recurrent nonsense mutation occurring as a de novo event in a patient with recessive dystrophic epidermolysis bullosa.
    Cuadrado-Corrales N; Sánchez-Jimeno C; García M; Ayuso C; De Lucas R; Vicario JL; Conti CJ; Zambruno G; Escamez MJ; Del Rio M
    Dermatology; 2011; 223(3):219-21. PubMed ID: 21849769
    [No Abstract]   [Full Text] [Related]  

  • 67. Significance of sentinel node biopsy in the management of squamous cell carcinoma arising from recessive dystrophic epidermolysis bullosa.
    Rokunohe A; Nakano H; Aizu T; Kaneko T; Nakajima K; Ikenaga S; Matsuzaki Y; Murai T; Tamai K; Sawamura D
    J Dermatol; 2008 Jun; 35(6):336-40. PubMed ID: 18578710
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Epidermolysis Bullosa (EB) Acquisita in an Adult Patient with Previously Unrecognized Mild Dystrophic EB and Biallelic COL7A1 Mutations.
    Guerra L; Condorelli AG; Fortugno P; Calabresi V; Pedicelli C; Di Zenzo G; Castiglia D
    Acta Derm Venereol; 2018 Apr; 98(4):411-415. PubMed ID: 29182795
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Mutation analysis and characterization of COL7A1 mutations in dystrophic epidermolysis bullosa.
    Dang N; Murrell DF
    Exp Dermatol; 2008 Jul; 17(7):553-68. PubMed ID: 18558993
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Basic fibroblast growth factor: a missing link between collagen VII, increased collagenase, and squamous cell carcinoma in recessive dystrophic epidermolysis bullosa.
    Arbiser JL; Fine JD; Murrell D; Paller A; Connors S; Keough K; Marsh E; Folkman J
    Mol Med; 1998 Mar; 4(3):191-5. PubMed ID: 9562977
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Normal molecular weight of type VII collagen produced by recessive dystrophic epidermolysis bullosa keratinocytes.
    Jenison M; Fine JD; Gammon WR; O'Keefe EJ
    J Invest Dermatol; 1993 Jan; 100(1):93-6. PubMed ID: 8423408
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Thrombospondin-1 Is a Major Activator of TGF-β Signaling in Recessive Dystrophic Epidermolysis Bullosa Fibroblasts.
    Atanasova VS; Russell RJ; Webster TG; Cao Q; Agarwal P; Lim YZ; Krishnan S; Fuentes I; Guttmann-Gruber C; McGrath JA; Salas-Alanis JC; Fertala A; South AP
    J Invest Dermatol; 2019 Jul; 139(7):1497-1505.e5. PubMed ID: 30684555
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Cancer. An anchor for tumor cell invasion.
    Yuspa SH; Epstein EH
    Science; 2005 Mar; 307(5716):1727-8. PubMed ID: 15774745
    [No Abstract]   [Full Text] [Related]  

  • 74. The inversa type of recessive dystrophic epidermolysis bullosa is caused by specific arginine and glycine substitutions in type VII collagen.
    van den Akker PC; Mellerio JE; Martinez AE; Liu L; Meijer R; Dopping-Hepenstal PJ; van Essen AJ; Scheffer H; Hofstra RM; McGrath JA; Jonkman MF
    J Med Genet; 2011 Mar; 48(3):160-7. PubMed ID: 21113014
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Collagen VII plays a dual role in wound healing.
    Nyström A; Velati D; Mittapalli VR; Fritsch A; Kern JS; Bruckner-Tuderman L
    J Clin Invest; 2013 Aug; 123(8):3498-509. PubMed ID: 23867500
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Characterization of mutations of the type VII collagen gene (COL7A1) in recessive dystrophic epidermolysis bullosa mitis (M-RDEB) from three Korean patients.
    Ryoo YW; Kim BC; Lee KS
    J Dermatol Sci; 2001 Jun; 26(2):125-32. PubMed ID: 11378329
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A microinjected COL7A1-PAC vector restores synthesis of intact procollagen VII in a dystrophic epidermolysis bullosa keratinocyte cell line.
    Mecklenbeck S; Compton SH; Mejía JE; Cervini R; Hovnanian A; Bruckner-Tuderman L; Barrandon Y
    Hum Gene Ther; 2002 Sep; 13(13):1655-62. PubMed ID: 12228020
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Translating the combination of gene therapy and tissue engineering for treating recessive dystrophic epidermolysis bullosa.
    Dakiw Piaceski A; Larouche D; Ghani K; Bisson F; Cortez Ghio S; Larochelle S; Moulin VJ; Caruso M; Germain L
    Eur Cell Mater; 2018 Feb; 35():73-86. PubMed ID: 29441510
    [TBL] [Abstract][Full Text] [Related]  

  • 79. An RNA-targeted therapy for dystrophic epidermolysis bullosa.
    Peking P; Koller U; Duarte B; Murillas R; Wolf S; Maetzig T; Rothe M; Kocher T; García M; Brachtl G; Schambach A; Larcher F; Reichelt J; Bauer JW; Murauer EM
    Nucleic Acids Res; 2017 Sep; 45(17):10259-10269. PubMed ID: 28973459
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Mild recessive dystrophic epidermolysis bullosa associated with two compound heterozygous COL7A1 mutations.
    von Bartenwerffer W; Has C; Arin MJ; Tantcheva-Poór I; Kreuter A; Kremer K; Arshah T; Hoffmann M; Eming SA; Kohlhase J; Krieg T; Bruckner-Tuderman L; Hartmann K
    Eur J Dermatol; 2011; 21(2):170-2. PubMed ID: 21382783
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.